324 related articles for article (PubMed ID: 20332136)
1. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Veronesi P; Torrisi R; Montagna E; Luini A; Intra M; Gentilini O; Ghisini R; Goldhirsch A; Colleoni M
Ann Oncol; 2010 Oct; 21(10):1974-1981. PubMed ID: 20332136
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
4. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
5. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
7. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
9. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
[TBL] [Abstract][Full Text] [Related]
10. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study.
Agresti R; Sandri M; Gennaro M; Bianchi G; Maugeri I; Rampa M; Capri G; Carcangiu ML; Trecate G; Riggio E; Lozza L; de Braud F
Clin Breast Cancer; 2017 Jun; 17(3):219-231. PubMed ID: 28087389
[TBL] [Abstract][Full Text] [Related]
13. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
14. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.
Murphy BL; Day CN; Hoskin TL; Habermann EB; Boughey JC
Ann Surg Oncol; 2018 Aug; 25(8):2241-2248. PubMed ID: 29786125
[TBL] [Abstract][Full Text] [Related]
16. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Colleoni M; Cole BF; Viale G; Regan MM; Price KN; Maiorano E; Mastropasqua MG; Crivellari D; Gelber RD; Goldhirsch A; Coates AS; Gusterson BA
J Clin Oncol; 2010 Jun; 28(18):2966-73. PubMed ID: 20458051
[TBL] [Abstract][Full Text] [Related]
17. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
[No Abstract] [Full Text] [Related]
18. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes.
Chun YS; Mizuno T; Cloyd JM; Ha MJ; Omichi K; Tzeng CD; Aloia TA; Ueno NT; Kuerer HM; Barcenas CH; Vauthey JN
Eur J Surg Oncol; 2020 Sep; 46(9):1588-1595. PubMed ID: 32253074
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y
Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
[TBL] [Abstract][Full Text] [Related]
20. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
